Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic Lymphocytic Leukemia

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium


T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24–71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6–31%) and 21% (95% CI, 7–34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood 1991; 78: 3269–3274.

    CAS  PubMed  Google Scholar 

  2. Brunning RD . T-prolymphocytic leukaemia. Blood 1991; 78: 3111–3113.

    CAS  PubMed  Google Scholar 

  3. Catovsky D, Ralfkiaer E, Muller-Hermelink HK . T-cell prolymphocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 195–196.

    Google Scholar 

  4. Catovsky D, Matutes E, Dearden C, Osuji N, Brito-Babapulle V . The WHO classification of matureT-cell leukemias. Blood 2004; 104: 2989–2990.

    Article  CAS  PubMed  Google Scholar 

  5. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D . A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004; 104: 328–335.

    Article  CAS  PubMed  Google Scholar 

  6. Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ et al. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 2009; 94: 518–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dearden CE, Matules E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B et al. High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H. Blood 2001; 98: 1721–1726.

    Article  CAS  PubMed  Google Scholar 

  8. Collins RH, Pineiro LA, Agura ED, Fay JW . Treatment of T prolymphocytic leukaemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 627–628.

    Article  CAS  PubMed  Google Scholar 

  9. Garderet L, Bittencourt H, Kaliski A, Daniel MT, Ribaud P, Socie G et al. Treatment of T-prolymphocytic leukaemia with nonmyeloablatove allogeneic stem cell transplantation. Eur J Haematol 2001; 66: 137–139.

    Article  CAS  PubMed  Google Scholar 

  10. Murase K, Matsunaga T, Sato T, Kuribayashi K, Kogawa K, Kawano Y et al. Allogeneic bone marrow transplantation in a patient with T-prolyphocytic leukaemia with small-intestinal involvement. Int J Clin Oncol 2003; 8: 391–394.

    Article  PubMed  Google Scholar 

  11. Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K et al. Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukaemia. Rinsho Ketsueki 2005; 46: 527–531.

    PubMed  Google Scholar 

  12. Curtin NJ, Schwarer AP . Nonmyeloablative peripheral stem cell transplant for T prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor AB0 incompatibility. Clin Lab Haematol 2005; 27: 206–208.

    Article  CAS  PubMed  Google Scholar 

  13. DeLavallade H, Faucher C, Furst S, El-Cheikh J, Vey N, Coso D et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukaemia: graft-versus-tumor effect and long-term remission. Bone Marrow Tranplant 2006; 37: 709–710.

    Article  CAS  Google Scholar 

  14. Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 2010; 149: 907–910.

    Article  PubMed  Google Scholar 

  15. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortem J, Maziarz RT et al. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 2010; 16: 1–5.

    Article  Google Scholar 

  16. Rieger M, Brüggemann M, Dietrich S, Hegenbart U, Hensel M, Moos M et al. T-prolymphocytic leukemia (T-PLL) is sensitive to graft-versus-leukemia effects: Evidence from minimal residual disease (MRD) kinetics. Haematologica 2009; 94 (Suppl.3): S75–S76 (abstract).

    Google Scholar 

Download references


We acknowledge all collaborating EBMT Investigators and Institutions that contributed cases to this study listed in the Appendix. Moreover, we also acknowledge Investigators and Centers that were consulted and whose cases were disqualified from the analysis.

Author information

Authors and Affiliations



Corresponding author

Correspondence to W Wiktor-Jedrzejczak.

Ethics declarations

Competing interests

The authors declare no conflict of interest.



Table A1

Table a1 List of participating investigators

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wiktor-Jedrzejczak, W., Dearden, C., de Wreede, L. et al. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia 26, 972–976 (2012).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • prolymphocytic leukemia
  • bone marrow transplantation
  • graft versus leukemia

This article is cited by


Quick links